The poor outcomes seen in this subset of patients are believed to be a result of the unique biology of the leukemia cells, with approximately 80% of cases carrying a translocation that results in the rearrangement of KMT2A (KMT2Ar) and its fusion to one of more than 130 different partner genes3. This evidence concerns the gene KMT2A and leukemia.